Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …

Background: The COMPASS trial (Cardiovascular Outcomes for People using
Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with …

Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …

Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …

Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …

Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …

Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …

Background To date, there are no data on switching to dual pathway inhibition (DPI) patients
who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …